Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC

This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins contained in the DRibble vaccine and the protein antigens targeted by this strong immune response will include common antigens shared by both the vaccine and the patient's tumor.

Study Overview

• Status: Completed
• Conditions: Carcinoma, Non-Small-Cell Lung
• Intervention / Treatment: Drug: Cyclophosphamide; Biological: DRibble vaccine; Biological: HPV vaccine; Drug: Imiquimod; Drug: GM-CSF

Detailed Description

This is an open-label, randomized study in which the first 33 patients will be assigned to receive the either:

• DRibbles vaccine and HPV vaccine
• DRibbles vaccine, HPV vaccine, and imiquimod
• DRibbles vaccine, HPV vaccine, and GM-CSF After 11 patients have been assigned to each group, the study arm with the greatest number of vaccine-induced strong antibody responses will then continue with enrollment of 15 further patients. The primary objective is to determine the best strategy to induce strong (>15 fold) tumor-specific or tumor-associated antibody responses in patients with stage III A and B NSCLC. The goal is to select one regimen to advance to additional clinical trials.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Louisiana
    • New Orleans, Louisiana, United States, 70112
      • LSU Stanley S. Scott Cancer Center
  • Oregon
    • Portland, Oregon, United States, 97213
      • Providence Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Stage IIIA or IIIB histologically proven non-small cell lung cancer
• Completion of definitive therapy
• Enrollment from 28 days to 12 weeks from completion of definitive therapy
• Toxicities from definitive therapy resolved to less than grade 1
• ECOG performance status 0-1
• Negative pregnancy test in women of childbearing potential
• Agree to avoid pregnancy or fathering a child while on study treatment
• Ability to give informed consent and comply with protocol
• Anticipated survival minimum of 6 months
• Prior therapy with investigational agents must be completed at least 3 weeks prior to study enrollment
• Normal organ and marrow function as defined by specific lab tests
• Archived tumor tissue available

Exclusion Criteria:

• Active autoimmune disease except for vitilogo or hypothyroidism
• Active other malignancy
• Known HIV+ and/or Hepatitis B or C positive
• Medical or psychiatric conditions that would preclude safe participation
• Ongoing chemotherapy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: DRibble Vaccine Alone; Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.	Drug: Cyclophosphamide; Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.; Other Names: Cytoxin; Biological: DRibble vaccine; DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.; Biological: HPV vaccine; Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.; Other Names: Ceravix
Experimental: DRibble vaccine with imiquimod; Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4) and for four days following each vaccine cycle. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.	Drug: Cyclophosphamide; Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.; Other Names: Cytoxin; Biological: DRibble vaccine; DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.; Biological: HPV vaccine; Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.; Other Names: Ceravix; Drug: Imiquimod; Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.; Other Names: Aldara
Experimental: DRibble vaccine with GM-CSF; Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.	Drug: Cyclophosphamide; Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.; Other Names: Cytoxin; Biological: DRibble vaccine; DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.; Biological: HPV vaccine; Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.; Other Names: Ceravix; Drug: GM-CSF; GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.; Other Names: Leukine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identify the regimen that produces the strongest antibody response	The best regimen will be defined as the one that generates the greatest increase in the number of strong antibody responses as defined by a greater than 15-fold increase in antibody, as measured using the Immune Response Biomarker Profiling Array (Invitrogen) on the day 95 serum sample.	95 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety	To evaluate the overall safety of allogeneic NSCLC DRibble vaccine alone or in combination with either imiquimod or GM-CSF, as adjuvant treatment for definitively-treated patients with Stage IIIA or B NSCLC. During the treatment period, patients will be seen in clinic 13 times over a 22-week period; performance status and side-effects will be evaluated at each visit.	43 weeks
Progression free survival	Evaluate progression-free survival. Tumor measurements by CT scan will be obtained at week 16 and subsequently at the discretion of the treating investigator. After the treatment period, patients will be seen every 3 months for 2 years, or until progressive disease.	2 years
Immune response and progression-free survival correlation.	Evaluate whether any immune response data correlate with progression-free survival. Immune response data will be collected 12 times over the first 43 weeks and then every 3 months until two years or progressive disease. This data will be correlated with progression-free survival.	2 years

Collaborators and Investigators

• Sponsor: UbiVac
• Collaborators: National Cancer Institute (NCI); Mayo Clinic; Louisiana State University Health Sciences Center in New Orleans; Providence Health & Services; Providence Cancer Center, Earle A. Chiles Research Institute
• Investigators: Study Director: Bernard Fox, PhD, UbiVac

Study record dates

Study Major Dates

• Study Start: July 1, 2013
• Primary Completion (Actual): November 1, 2016
• Study Completion (Actual): April 1, 2017

Study Registration Dates

• First Submitted: July 24, 2013
• First Submitted That Met QC Criteria: July 24, 2013
• First Posted (Estimate): July 26, 2013

Study Record Updates

• Last Update Posted (Actual): July 6, 2017
• Last Update Submitted That Met QC Criteria: July 3, 2017
• Last Verified: July 1, 2017

More Information

Terms related to this study

• Keywords: Lung cancer; Cyclophosphamide; GM-CSF; Imiquimod; DRibble Vaccine; HPV vaccine (Ceravix)
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Adjuvants, Immunologic; Interferon Inducers; Cyclophosphamide; Vaccines; Imiquimod
• Other Study ID Numbers: UbiVac DPV-001; R44CA121612 (U.S. NIH Grant/Contract)